A. Menarini International Licensing S.A.
2 products tracked · names used in filings: A. Menarini International Licensing S.A.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 28 Sep 2026🇪🇺 Expected EC decisionestimate
Evlarco (obicetrapib;ezetimibe): expected EC decision
Estimated as CHMP opinion (2026-07-23) + 67 days, the standard Commission decision period. Not an official date. · A. Menarini International Licensing S.A. · source
Mon 28 Sep 2026🇪🇺 Expected EC decisionestimate
Ubeslo (obicetrapib): expected EC decision
Estimated as CHMP opinion (2026-07-23) + 67 days, the standard Commission decision period. Not an official date. · A. Menarini International Licensing S.A. · source
Thu 23 Jul 2026🇪🇺 CHMP positive opinion
Evlarco (obicetrapib;ezetimibe): CHMP positive opinion
Thu 23 Jul 2026🇪🇺 CHMP positive opinion
Ubeslo (obicetrapib): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Evlarco obicetrapib;ezetimibe | Opinion | |
| 🇪🇺 | Ubeslo obicetrapib | Opinion |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.